Semin Respir Crit Care Med 2002; 23(5): 457-470
DOI: 10.1055/s-2002-35717
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Guidelines for Treatment of Hospital-Acquired Pneumonia

Christian Brun-Buisson
  • Hôpital Henri Mondor, Université Paris-12, Créteil, France
Further Information

Publication History

Publication Date:
25 November 2002 (online)

ABSTRACT

In the past decade, much information has been gained on the diagnostic and therapeutic strategies in patients suspected of having hospital-acquired pneumonia. The key to an effective therapeutic approach is the diagnostic strategy used, and timely administration of appropriate antibiotic therapy. Many patients, but not all, need early appropriate empiric therapy. This decision and the selection of the initial regimen is based on local epidemiological and surveillance data, the clinical presentation, and the recent history of the individual patient; direct examination of reliable respiratory tract samples can provide a valuable help, but cannot be relied on solely. Whenever possible, the timely performance of such samples (i.e., before instituting therapy) is of paramount importance because this will bear heavily on their interpretation and the conduct of subsequent and definitive therapy. Hospitals are now plagued with infection caused by increasingly multidrug-resistant organisms; this is especially the case in intensive care units (ICUs), where nosocomial respiratory tract infection is the primary reason for prescribing antibiotics. Although many questions remain unanswered regarding the optimal choices and duration of therapy, reversing this trend will require continuous and prolonged efforts to strictly adhere to a rigorous approach for antibiotic prescribing in nosocomial respiratory tract infection.

REFERENCES

  • 1 George D L. Epidemiology of nosocomial ventilator-associated pneumonia.  Infect Control Hosp Epidemiol . 1993;  14 163-169
  • 2 Fagon J Y, Chastre J, Trouillet J L, Pierre J, Darne C, Gibert C. Nosocomial pneumonia in patients receiving continuous mechanical ventilation: prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques.  Am Rev Respir Dis . 1989;  139 877-884
  • 3 Vincent J L, Bihari D J, Suter P M. The prevalence of nosocomial infection in intensive care in Europe: results of the European prevalence of infection in intensive care (EPIC) study.  JAMA . 1995;  274 639-644
  • 4 Alberti C, Brun-Buisson C, Burchardi H. Epidemiology of sepsis and infection in ICU patients from an international multicenter cohort study.  Intensive Care Med . 2002;  28 108-121
  • 5 Bergmans D C, Bonten M JM, Gaillard C A. Indications for antibiotic use in ICU patients: a one-year prospective surveillance.  J Antimicrob Chemother . 1997;  39 527-535
  • 6 Alvarez-Lerma F, the ICU-Acquired Pneumonia Study Group. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit.  Intensive Care Med . 1996;  22 387-394
  • 7 Rello J, Gallego M, Mariscal D, Sonora R, Vallés J. The value of routine microbial investigation in ventilator-associated pneumonia.  Am J Respir Crit Care Med . 1997;  156 196-200
  • 8 Sanchez-Nieto J M, Torres A, Garcia-Cordoba F. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study.  Am J Respir Crit Care Med . 1998;  157 371-376
  • 9 Kollef M H, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia.  Chest . 1998;  113 412-420
  • 10 Luna C M, Vujacich P, Niederman M S. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia.  Chest . 1997;  111 676-685
  • 11 Dupont H, Mentec H, Sollet J P, Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia.  Intensive Care Med . 2001;  27 355-362
  • 12 Solé-Violan J, Fernandez J A, Benitez A B, Cardenosa Cendrero A J, Rodriguez de Castro F. Impact of quantitative invasive diagnostic techniques in the management and outcome of mechanically ventilated patients with suspected pneumonia.  Crit Care Med . 2000;  28 2737-2741
  • 13 Kollef M H, Fraser V J. Antibiotic resistance in the intensive care unit.  Ann Intern Med . 2001;  134 298-314
  • 14 The Hospital Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention. Intensive Care Antimicrobial Resistance Epidemiology (ICARE) surveillance report, data summary from January 1996 through December 1997.  Am J Infect Control . 1999;  27 279-284
  • 15 Kollef M H, Sherman G, Ward S, Fraser V J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.  Chest . 1999;  115 462-474
  • 16 Andrews C P, Coalson J J, Smith J D, Johanson W G. Diagnosis of nosocomial bacterial pneumonia in acute, diffuse lung injury.  Chest . 1981;  80 254-258
  • 17 Delclaux C, Roupie E, Blot F, Brochard L, Lemaire F, Brun-Buisson C. Lower respiratory tract colonization and infection during severe acute respiratory distress syndrome: incidence and diagnosis.  Am J Respir Crit Care Med . 1997;  156 1092-1098
  • 18 Fagon J Y, Chastre J, Hance A J. Detection of nosocomial lung infection in ventilated patients: use of a protected brush specimen and quantitative culture techniques in 147 patients.  Am Rev Respir Dis . 1988;  138 110-116
  • 19 Meduri G U, Mauldin G L, Wunderink R G. Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia.  Chest . 1994;  106 221-235
  • 20 Torres A, El Ebiary M, Padro L. Validation of different techniques for the diagnosis of ventilator-associated pneumonia: comparison with immediate post-mortem biopsy.  Am J Respir Crit Care Med . 1994;  149 324-331
  • 21 Pugin J, Auckenthaler R, Mili N, Janssens J P, Lew P D, Suter P M. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic ``blind'' bronchoalveolar lavage fluid.  Am Rev Respir Dis . 1991;  143 1121-1129
  • 22 Singh N, Falestiny M N, Rogers P. Pulmonary infiltrates in the surgical ICU: prospective assessment of predictors of etiology and mortality.  Chest . 1998;  114 1120-1136
  • 23 Johanson W G, Seidenfeld J J, Gomez P, De Los Santos R, Coalson J J. Bacteriologic diagnosis of nosocomial pneumonia following prolonged mechanical ventilation.  Am Rev Respir Dis . 1988;  137 259-264
  • 24 Singh N, Rogers P, Atwood C W, Wagener M M, Yu V L. Short-course Empiric Antibiotic Therapy for Patients with Pulmonary Infiltrates in the Intensive Care Unit: a proposed solution for indiscriminate antibiotic prescription.  Am J Respir Crit Care Med . 2000;  162 505-511
  • 25 Bonten M J, Froon A HM, Gaillard C A. The systemic inflammatory response in the development of ventilator-associated pneumonia.  Am J Respir Crit Care Med . 1997;  156 1105-1113
  • 26 Froon A HM, Bonten M J, Gaillard C A. Prediction of clinical severity and outcome of ventilator-associated pneumonia: comparison of simplified acute physiology score with systemic inflammatory mediators.  Am J Respir Crit Care Med . 1998;  158 1026-1031
  • 27 Bonten M J, Bergmans D C, Stobberingh E E. Implementation of bronchoscopic techniques in the diagnosis of ventilator-associated pneumonia to reduce antibiotic use.  Am J Respir Crit Care Med . 1997;  156 1820-1824
  • 28 Blot F, Raynard B, Chachaty E, Tancrede C, Antoun S, Nitenberg G. Value of gram stain examination of lower respiratory tract secretions for early diagnosis of nosocomial pneumonia.  Am J Respir Crit Care Med . 2000;  162 1731-1737
  • 29 Lambert R S, Vereen L E, George R B. Comparison of tracheal aspirates and protected brush catheter specimens for identifying pathogenic bacteria in mechanically ventilated patients.  Am J Med Sci . 1989;  297 377-382
  • 30 Chastre J, Fagon J Y, Soler P. Diagnosis of nosocomial bacterial pneumonia in intubated patients undergoing ventilation: comparison of the usefulness of bronchoalveolar lavage and the protected specimen brush.  Am J Med . 1988;  85 499-506
  • 31 Chastre J, Fagon J Y, Bornet-Lecso M. Evaluation of bronchoscopic techniques for the diagnosis of nosocomial pneumonia.  Am J Respir Crit Care Med . 1995;  152 231-240
  • 32 Allaouchiche B, Jaumain H, Dumontet C, Motin J. Early diagnosis of ventilator-associated pneumonia: is it possible to define a cutoff value of infected cells in BAL fluid?.  Chest . 1996;  110 1558-1565
  • 33 Souweine B, Veber B, Bedos J P. Diagnostic accuracy of protected specimen brush and bronchoalveolar lavage in nosocomial pneumonia: impact of previous antimicrobial treatments.  Crit Care Med . 1998;  26 236-244
  • 34 Timsit J F, Misset B, Renaud B, Goldstein F W, Carlet J. Effect of previous antimicrobial therapy on the accuracy of the main procedures used to diagnose nosocomial pneumonia in patients who are using mechanical ventilation.  Chest . 1995;  108 1036-1040
  • 35 Chevret S, Hemmer M, Carlet J, Langer M. Incidence and risk factors of pneumonia acquired in intensive care units: results from a multicenter prospective study on 996 patients. European Cooperative Group on Nosocomial Pneumonia.  Intensive Care Med . 1993;  19 256-264
  • 36 Langer M, Cigada M, Mandelli M, Mosconi P, Tognoni G, the ICUGIC. Early onset pneumonia: a multicenter study in intensive care units.  Intensive Care Med . 1987;  13 342-346
  • 37 Rello J, Diaz E, Roque M, Valles J. Risk factors for developing pneumonia within 48 hours of intubation.  Am J Respir Crit Care Med . 1999;  159 1742-1746
  • 38 Ibrahim E H, Ward S, Sherman G, Kollef M H. A comparative analysis of patients with early-onset vs late-onset nosocomial pneumonia in the ICU setting.  Chest . 2000;  117 1434-1442
  • 39 Johanson W G, Pierce A K, Sanford J P. Changing pharyngeal bacterial flora of hospitalized patients: emergence of gram-negative bacilli.  N Engl J Med . 1969;  281 1137-1140
  • 40 Trouillet J L, Chastre J, Vuagnat A. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria.  Am J Respir Crit Care Med . 1998;  157 531-539
  • 41 Bonten M J, Bergmans D C, Speijer H, Stobberingh E E. Characteristics of polyclonal endemicity of Pseudomonas aeruginosa colonization in intensive care units: implications for infection control.  Am J Respir Crit Care Med . 1999;  160 1212-1219
  • 42 Rello J, Sa-Borges M, Correa H, Leal S R, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices.  Am J Respir Crit Care Med . 1999;  160 608-613
  • 43 Pham L H, Brun-Buisson C, Legrand P. Diagnosis of nosocomial pneumonia in mechanically ventilated patients: comparison of a plugged telescoping catheter with the protected specimen brush.  Am Rev Respir Dis . 1991;  143 1055-1061
  • 44 Cook D J, Kollef M H. Risk factors for ICU-acquired pneumonia.  JAMA . 1998;  279 1605-1606
  • 45 Flynn D M, Weinstein R A, Nathan C, Gaston M A, Kabins S A. Patient's endogenous flora as the source of ``nosocomial'' Enterobacter in cardiac surgery.  J Infect Dis . 1987;  136 363-368
  • 46 Trouillet J L, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms.  Clin Infect Dis . 2002;  34 1047-1054
  • 47 American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies: a consensus statement.  Am J Respir Crit Care Med . 1996;  153 1711-1725
  • 48 Heyland D K, Cook D J, Marshall J C. The clinical utility of invasive diagnostic techniques in the setting of ventilator-associated pneumonia.  Chest . 1999;  115 1076-1084
  • 49 Fagon J Y, Chastre J, Wolff M. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: a randomized trial.  Ann Intern Med . 2000;  132 621-630
  • 50 Mier L, Dreyfuss D, Darchy B. Is penicillin G an adequate initial treatment for aspiration pneumonia?.  <~>A prospective evaluation using protected specimen brush and quantitative cultures. Intensive Care Med . 1993;  19 279-284
  • 51 Fink M P, Snydman D R, Niederman M S. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin.  Antimicrob Agents Chemother . 1994;  38 547-557
  • 52 Carmeli Y, Troillet N, Eliopoulos G M, Samore M H. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents.  Antimicrob Agents Chemother . 1999;  43 1379-1382
  • 53 Fish D N, Piscitelli S C, Danziger L H. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies.  Pharmacotherapy . 1995;  15 279-291
  • 54 Harris A D, Smith D, Johnson J A, Bradham D D, Roghmann M C. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients.  Clin Infect Dis . 2002;  34 340-345
  • 55 Wolff M, the Cefpirome Pneumonia Study Group. Comparison of strategies using cefpirome and ceftazidime for empiric treatment of pneumonia in intensive care patients.  Antimicrob Agents Chemother . 1998;  42 28-36
  • 56 Beaucaire G, Nicolas M H, Martin C. Etude Phare: etude comparative de l'association céfépime-amikacine versus ceftazidime en association avec l'amikacine dans le traitement des pneumonies nosocomiales chez les patients ventilés.  Ann Fr Anesth Réan . 1999;  18 186-195
  • 57 Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.  Intensive Care Med . 2001;  27 493-502
  • 58 Brun-Buisson C, Sollet J P, Schweich H, Brière S, Petit C, the VAP Study Group. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial.  Clin Infect Dis . 1998;  26 346-354
  • 59 Joshi M, Bernstein J, Solomkin J, Wester B A, Kuye O. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group.  J Antimicrob Chemother . 1999;  43 389-397
  • 60 Sieger B, Berman S Z, Geckler R W, Farkas S A, the Meropenem Lower Respiratory Infection Group. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study.  Crit Care Med . 1997;  25 1663-1670
  • 61 Fagon J, Patrick H, Haas D W. Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.  Am J Respir Crit Care Med . 2000;  161 753-762
  • 62 Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.  Clin Infect Dis . 2001;  32 402-412
  • 63 Laforce F M. Systemic antimicrobial therapy of nosocomial pneumonia: monotherapy versus combination therapy.  Eur J Clin Microbiol Infect Dis . 1989;  8 61-68
  • 64 Arbo M D, Snydman D R. Monotherapy is appropriate for nosocomial pneumonia in the intensive care unit.  Semin Respir Infect . 1993;  8 259-267
  • 65 Lynch J PI. Combination therapy is appropriate for nosocomial pneumonia in the intensive care unit.  Semin Respir Infect . 1993;  8 268-284
  • 66 Cometta A, Baumgartner J D, Lew D. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients.  Antimicrob Agents Chemother . 1994;  38 1309-1313
  • 67 Hilf M, Yu V L, Sharp J. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients.  Am J Med . 1989;  87 540-546
  • 68 Moore R, Smith C R, Lietman P S. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia.  Am J Med . 1984;  77 657-662
  • 69 Kashuba A D, Nafziger A N, Drusano G L, Bertino Jr S J. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria.  Antimicrob Agents Chemother . 1999;  43 623-629
  • 70 Thomas J K, Forrest A, Bhavnani S M. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy.  Antimicrob Agents Chemother . 1998;  42 521-527
  • 71 Rello J, Mariscal D, March F. Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection?.  Am J Respir Crit Care Med . 1998;  157 912-916
  • 72 Schentag J J. Antimicrobial management strategies for gram-positive bacterial resistance in the intensive care unit.  Crit Care Med . 2001;  29 100-107
  • 73 Ruiz M, Torres A, Ewig S. Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome.  Am J Respir Crit Care Med . 2000;  162 119-125
    >